OBJECTIVE: Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS) that measures aspects of ADHD in adults. METHOD: Psychometric properties of the AISRS total and AISRS subscales are analyzed and compared to the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) and the Clinical Global Impression-ADHD-Severity Scale using data from a placebo-controlled 6-month clinical trial of once-daily atomoxetine. RESULTS: The AISRS has high internal consistency, good convergent, and discriminant validities; modest divergent validity; and small ceiling and floor effects (<or=1%). It correlates highly with the CAARS-Inv:SV. Factor analysis confirms 2 AISRS subscales, hyperactivity-impulsive scale and inattention. The AISRS total and AISRS subscales perform stably. All scales demonstrate responsiveness to change with medication. CONCLUSION: The AISRS and its subscales are robust, valid efficacy measures of ADHD symptoms in adult patients. Its anchored items and semistructured interview are advancements over existing scales.
RCT Entities:
OBJECTIVE: Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS) that measures aspects of ADHD in adults. METHOD: Psychometric properties of the AISRS total and AISRS subscales are analyzed and compared to the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) and the Clinical Global Impression-ADHD-Severity Scale using data from a placebo-controlled 6-month clinical trial of once-daily atomoxetine. RESULTS: The AISRS has high internal consistency, good convergent, and discriminant validities; modest divergent validity; and small ceiling and floor effects (<or=1%). It correlates highly with the CAARS-Inv:SV. Factor analysis confirms 2 AISRS subscales, hyperactivity-impulsive scale and inattention. The AISRS total and AISRS subscales perform stably. All scales demonstrate responsiveness to change with medication. CONCLUSION: The AISRS and its subscales are robust, valid efficacy measures of ADHD symptoms in adult patients. Its anchored items and semistructured interview are advancements over existing scales.
Authors: Irene J Elkins; Gretchen R B Saunders; Stephen M Malone; Sylia Wilson; Matt McGue; William G Iacono Journal: Drug Alcohol Depend Date: 2020-02-27 Impact factor: 4.492
Authors: Jessica Abrams; Stephen V Faraone; K Yvonne Woodworth; Thomas J Spencer; Itai Biederman; Joseph Biederman Journal: J Nerv Ment Dis Date: 2018-09 Impact factor: 2.254
Authors: Frances R Levin; John J Mariani; Sheila Specker; Marc Mooney; Amy Mahony; Daniel J Brooks; David Babb; Yun Bai; Lynn E Eberly; Edward V Nunes; John Grabowski Journal: JAMA Psychiatry Date: 2015-06 Impact factor: 21.596
Authors: Hao-Jie Zhu; Kennerly S Patrick; John S Markowitz Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2011-02-25 Impact factor: 3.205
Authors: Frances R Levin; C Jean Choi; Martina Pavlicova; John J Mariani; Amy Mahony; Daniel J Brooks; Edward V Nunes; John Grabowski Journal: Drug Alcohol Depend Date: 2018-05-01 Impact factor: 4.492
Authors: Thomas J Spencer; Pradeep Bhide; Jinmin Zhu; Stephen V Faraone; Maura Fitzgerald; Amy M Yule; Mai Uchida; Andrea E Spencer; Anna M Hall; Ariana J Koster; Leah Feinberg; Sarah Kassabian; Barbara Storch; Joseph Biederman Journal: J Clin Psychiatry Date: 2018 Mar/Apr Impact factor: 4.384